Clinical Trial Update: Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term tolerability and safety of HYQVIA in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); results posted in 2024…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2024-08-28